製品番号: HY-156654

Ibuzatrelvir

(別名: PF-07817883)

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M^pro and 3CL^pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.90%
CAS 番号: 2755812-39-4
分子式: C₂₁H₃₀F₃N₅O₅
分子量:489.49

保管条件:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Ibuzatrelvir 構造式

CAS 番号: 2755812-39-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (2)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

SARS-CoV-2 3CL protease, COVID-19^[1]

体外実験

Ibuzatrelvir (0-10000 nM, 3 days) inhibits the SARS-CoV-1 M^pro and MERS M^pro activity with IC₅₀ values of 18 nM and 930 nM, respectively. Ibuzatrelvir demostrates a potent inhibitor of the proteolytic activity of SARS-CoV-2 M^pro as well as related human coronaviruses in VeroE6, MRC-5 or Vero81 cells^[4].
Ibuzatrelvir demonstrates potent SARS-CoV-2 antiviral cellular activity with EC₅₀ and EC₉₀ values of 34 nM and 70 nM respectively in differentiated normal human bronchial epithelial (dNHBE) cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Ibuzatrelvir (0-500 mg/kg, p.o., a single dose) inhibits virus replication in a dose-dependent manner in mouse- adapted SARS-CoV-2 animal model^[4].

Pharmacokinetics of Ibuzatrelvir in Rats and Monkeys^[1]

Species	Route/Dose(mg/kg)	CL_p (mL/min/kg)	V_d,ss (L/kg)	T_1/2 (h)	CL_renal (mL/min/kg)	C_max (ng/mL)	T_max (h)	AUC_{0 24} (ng·h/mL)	Oral F (%)	F_a × F_g^c (%)
Rat	i.v./1	34.4 (34.4, 34.4)	1.52 (1.67, 1.36)	10 (9.0, 11.2)	5.52 (3.25, 7.8)			481 (481, 481)
	p.o./7.5				-	606 (665, 547)	0.29 (0.083,0.50)	793 (704, 882)	21.9 (19.5, 24.3)	41.6 (37.19, 46.59)
Monkey	i.v./1	6.88 (5.46, 8.29)	0.657(0.591, 0.723)	2.77 (2.87, 2.67)	0.697 (0.0878,1.31)	-	-	2530 (3050, 2010)	-	-
	p.o./10	-	-	-	-	1510 (1650, 1360)	0.38 (0.25, 0.5)	7380 (8160, 6590)	29.2 (26.0, 32.3)	37.3 (40.8, 34.1)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

mouse-adapted SARS-CoV-2 animal model^[4].
Dosage:

0-500 mg/kg
Administration:

p.o., a single dose
Result:

Prevented weight loss and reduced the lung virus titer in mouse-adapted SARS-CoV-2 animal model

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 2755812-39-4
性状 Solid
分子量 489.49
分子式 C₂₁H₃₀F₃N₅O₅
Color White to off-white
SMILES

COC(N[C@@H](C(C)(C)C)C(N1[C@@H](C[C@H](C1)C(F)(F)F)C(N[C@H](C#N)C[C@H]2C(NCC2)=O)=O)=O)=O
別名

PF-07817883
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (2)

All

Sort by:

Journal Impact Factor

Nat Commun

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors. [Abstract]

2026 May 19. PMID: 42156379
ACS Pharmacol Transl Sci

2026 Jan 28.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (204.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0429 mL

10.2147 mL

20.4294 mL

5 mM

0.4086 mL

2.0429 mL

4.0859 mL

10 mM

0.2043 mL

1.0215 mL

2.0429 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Owen, et al. Preparation of peptidomimetic nitriles as SARS-CoV-2 3CL protease inhibitors and methods for the treatment of COVID-19. World Intellectual Property Organization, WO2021250648 A1. 2021-12-16.

[2]. Mahta Mortezavi, et al. Virologic Response and Safety After Oral Administration of Ibuzatrelvir, a Novel SARS-CoV-2 Mpro Inhibitor, in Non-Hospitalized Adults With Symptomatic COVID-19. European Congress of Clinical Microbiology and Infectious Disease (ECCMID) 2024; 2024 April 27-30.

[3]. Westberg M, et al. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations[J]. Sci Transl Med. 2024 Mar 13;16(738):eadi0979.

[4]. Allerton CMN, et al. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19[J]. J Med Chem. 2024 Apr 30. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0429 mL	10.2147 mL	20.4294 mL	51.0736 mL
	5 mM	0.4086 mL	2.0429 mL	4.0859 mL	10.2147 mL
	10 mM	0.2043 mL	1.0215 mL	2.0429 mL	5.1074 mL
	15 mM	0.1362 mL	0.6810 mL	1.3620 mL	3.4049 mL
	20 mM	0.1021 mL	0.5107 mL	1.0215 mL	2.5537 mL
	25 mM	0.0817 mL	0.4086 mL	0.8172 mL	2.0429 mL
	30 mM	0.0681 mL	0.3405 mL	0.6810 mL	1.7025 mL
	40 mM	0.0511 mL	0.2554 mL	0.5107 mL	1.2768 mL
	50 mM	0.0409 mL	0.2043 mL	0.4086 mL	1.0215 mL
	60 mM	0.0340 mL	0.1702 mL	0.3405 mL	0.8512 mL
	80 mM	0.0255 mL	0.1277 mL	0.2554 mL	0.6384 mL
	100 mM	0.0204 mL	0.1021 mL	0.2043 mL	0.5107 mL

Keywords

Ibuzatrelvir

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Ibuzatrelvir

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Orally Active Compound Library

Protease Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Ibuzatrelvir

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Ibuzatrelvir

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Orally Active Compound Library

Protease Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Ibuzatrelvir

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Ibuzatrelvir 関連分類

HY-156654 関連分類